Abstract
Background: Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease, which is characterized by an increased prevalence worldwide, which, in fact, tends to take extensive dimensions. The recent rapid development of science and technology has significantly contributed to the improvement of the management of type 1 diabetes mellitus, both in achieving the required euglycaemic regulation and reducing the psychological burden associated with the disease, consequently improving the quality of life of the patients with type 1 diabetes mellitus.
Methods: A literature review from 2010, related to the contribution of the modern insulin analogues, continuous glucose monitoring and the insulin pump, was performed using Scopus, ScienceDirect and PubMed databases.
Results: Studies included in the review support a direct and indirect association of technological innovations with the quality of life. The use of type 1 diabetes mellitus technology was negatively associated with the frequency of the hypoglycaemias and the value of the glycosylated hemoglobin, while at the same time, the development and use of the related technology were highly associated with an improvement in the quality of life.
Conclusion: Patients’ quality of life is an indicator of the management of type 1 diabetes mellitus, and it is just as important as glycaemic regulation. Through this review, it was concluded that a better quality of life of T1DM patients was associated with the improvement of glycosylated hemoglobin and hypoglycemic episodes.
Keywords: Type 1 diabetes mellitus, insulin analogues, continuous glucose monitoring, insulin pump therapy, quality of life, hypoglycaemia.
[1]
International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation 2019.
[2]
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl. 1): S14-31.
[http://dx.doi.org/10.2337/dc20-S002] [PMID: 31862745]
[http://dx.doi.org/10.2337/dc20-S002] [PMID: 31862745]
[3]
DCCT Research Group. Diabetes control and complications trial (DCCT): Update. Diabetes Care 1990; 13(4): 427-33.
[http://dx.doi.org/10.2337/diacare.13.4.427] [PMID: 2180661]
[http://dx.doi.org/10.2337/diacare.13.4.427] [PMID: 2180661]
[4]
Gubitosi-Klug RA. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Summary and future directions. Diabetes Care 2014; 37(1): 44-9.
[http://dx.doi.org/10.2337/dc13-2148] [PMID: 24356597]
[http://dx.doi.org/10.2337/dc13-2148] [PMID: 24356597]
[5]
American Diabetes Association. 7. Diabetes technology: Standards of medical care in diabetes-2019. Diabetes Care 2019; 42(Suppl. 1): S71-80.
[http://dx.doi.org/10.2337/dc19-S007] [PMID: 30559233]
[http://dx.doi.org/10.2337/dc19-S007] [PMID: 30559233]
[6]
Nawaz MS, Shah KU, Khan TM, et al. Evaluation of current trends and recent development in insulin therapy for management of diabetes mellitus. Diabetes Metab Syndr 2017; 11(Suppl. 2): S833-9.
[http://dx.doi.org/10.1016/j.dsx.2017.07.003] [PMID: 28709853]
[http://dx.doi.org/10.1016/j.dsx.2017.07.003] [PMID: 28709853]
[7]
Mian Z, Hermayer KL, Jenkins A. Continuous glucose monitoring: Review of an innovation in diabetes management. Am J Med Sci 2019; 358(5): 332-9.
[http://dx.doi.org/10.1016/j.amjms.2019.07.003] [PMID: 31402042]
[http://dx.doi.org/10.1016/j.amjms.2019.07.003] [PMID: 31402042]
[8]
Sora ND, Shashpal F, Bond EA, Jenkins AJ. Insulin pumps: Review of technological advancement in diabetes management. Am J Med Sci 2019; 358(5): 326-31.
[http://dx.doi.org/10.1016/j.amjms.2019.08.008] [PMID: 31655714]
[http://dx.doi.org/10.1016/j.amjms.2019.08.008] [PMID: 31655714]
[9]
Kravarusic J, Aleppo G. Diabetes technology use in adults with type 1 and type 2 diabetes. Endocrinol Metab Clin North Am 2020; 49(1): 37-55.
[http://dx.doi.org/10.1016/j.ecl.2019.10.006] [PMID: 31980120]
[http://dx.doi.org/10.1016/j.ecl.2019.10.006] [PMID: 31980120]
[10]
Ogden J. Health Psychology. A Textbook. 4th ed. Berkshire, England: Open University Press 2007.
[11]
World Health Organization. Programme on mental health : WHOQOL user manual, 2012 revision. World Health Organization 1998. Available from: https://apps.who.int/iris/handle/10665/ 77932
[12]
EQuality1 Study Group-Evaluation of QUALITY of Life and Costs in Diabetes Type 1, Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F, Bruttomesso D, et al. Quality of life and treatment satisfaction in adults with type 1 diabetes: A comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008; 25: 213-20.
[http://dx.doi.org/10.1111/j.1464-5491.2007.02346.x]
[http://dx.doi.org/10.1111/j.1464-5491.2007.02346.x]
[13]
Rys P, Pankiewicz O, Łach K, Kwaskowski A, Skrzekowska-Baran I, Malecki MT. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review. Diabetes Metab 2011; 37(3): 190-200.
[http://dx.doi.org/10.1016/j.diabet.2010.12.003] [PMID: 21333580]
[http://dx.doi.org/10.1016/j.diabet.2010.12.003] [PMID: 21333580]
[14]
Morrison V, Bennett P. An Introduction to Health Psychology. (2nd ed). Essex: Pearson Education Limited 2009.
[15]
DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial. BMJ 2002; 325(7367): 746.
[http://dx.doi.org/10.1136/bmj.325.7367.746] [PMID: 12364302]
[http://dx.doi.org/10.1136/bmj.325.7367.746] [PMID: 12364302]
[16]
Anderson BJ, Laffel LM, Domenger C, et al. Factors associated with diabetes-specific health-related quality of life in youth with type 1 diabetes: The Global TEENs study. Diabetes Care 2017; 40(8): 1002-9.
[http://dx.doi.org/10.2337/dc16-1990] [PMID: 28546221]
[http://dx.doi.org/10.2337/dc16-1990] [PMID: 28546221]
[17]
Al-Taie N, Maftei D, Kautzky-Willer A, Krebs M, Stingl H. Assessing the quality of life among patients with diabetes in Austria and the correlation between glycemic control and the quality of life. Prim Care Diabetes 2020; 14(2): 133-8.
[http://dx.doi.org/10.1016/j.pcd.2019.11.003] [PMID: 31859064]
[http://dx.doi.org/10.1016/j.pcd.2019.11.003] [PMID: 31859064]
[18]
American Diabetes Association. 7. Diabetes technology: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl. 1): S77-88.
[http://dx.doi.org/10.2337/dc20-S007] [PMID: 31862750]
[http://dx.doi.org/10.2337/dc20-S007] [PMID: 31862750]
[19]
Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: Getting better all the time. Nat Rev Endocrinol 2017; 13(7): 385-99.
[http://dx.doi.org/10.1038/nrendo.2017.39] [PMID: 28429780]
[http://dx.doi.org/10.1038/nrendo.2017.39] [PMID: 28429780]
[20]
Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev 2016; 2016(6): CD012161.
[http://dx.doi.org/10.1002/14651858.CD012161] [PMID: 27362975]
[http://dx.doi.org/10.1002/14651858.CD012161] [PMID: 27362975]
[21]
Almeida PHRF, Silva TBC, de Assis Acurcio F, et al. Quality of life of patients with type 1 diabetes mellitus using insulin analog glargine compared with NPH insulin: A systematic review and policy implications. Patient 2018; 11(4): 377-89.
[http://dx.doi.org/10.1007/s40271-017-0291-3] [PMID: 29322308]
[http://dx.doi.org/10.1007/s40271-017-0291-3] [PMID: 29322308]
[22]
van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther 2011; 13(6): 607-14.
[http://dx.doi.org/10.1089/dia.2010.0224] [PMID: 21457066]
[http://dx.doi.org/10.1089/dia.2010.0224] [PMID: 21457066]
[23]
Davis A, Kuriakose J, Clements JN. Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. Clin Pharmacokinet 2019; 58(4): 421-30.
[http://dx.doi.org/10.1007/s40262-018-0696-8] [PMID: 29978361]
[http://dx.doi.org/10.1007/s40262-018-0696-8] [PMID: 29978361]
[24]
Easa N, Alany RG, Carew M, Vangala A. A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade. Drug Discov Today 2019; 24(2): 440-51.
[http://dx.doi.org/10.1016/j.drudis.2018.11.010] [PMID: 30465877]
[http://dx.doi.org/10.1016/j.drudis.2018.11.010] [PMID: 30465877]
[25]
Barski L, Brandstaetter E, Sagy I, Jotkowitz A. Basal insulin for the management of diabetic ketoacidosis. Eur J Intern Med 2018; 47: 14-6.
[http://dx.doi.org/10.1016/j.ejim.2017.08.025] [PMID: 28864157]
[http://dx.doi.org/10.1016/j.ejim.2017.08.025] [PMID: 28864157]
[26]
Home PD. Plasma insulin profiles after subcutaneous injection: How close can we get to physiology in people with diabetes? Diabetes Obes Metab 2015; 17(11): 1011-20.
[http://dx.doi.org/10.1111/dom.12501] [PMID: 26041603]
[http://dx.doi.org/10.1111/dom.12501] [PMID: 26041603]
[27]
Peters CJ, Annan F, Hindmarsh PC, Thompson RJ. Insulin pump therapy. Paediatr Child Health 2021; 31: 129-40.
[http://dx.doi.org/10.1016/j.paed.2021.01.002]
[http://dx.doi.org/10.1016/j.paed.2021.01.002]
[28]
American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32(Suppl. 1): S13-61.
[http://dx.doi.org/10.2337/dc09-S013] [PMID: 19118286]
[http://dx.doi.org/10.2337/dc09-S013] [PMID: 19118286]
[29]
Pollock RF, Chubb B, Valentine WJ, Heller S. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes Metab Syndr Obes 2018; 11: 217-26.
[http://dx.doi.org/10.2147/DMSO.S156739] [PMID: 29844693]
[http://dx.doi.org/10.2147/DMSO.S156739] [PMID: 29844693]
[30]
Hemmingsen B, Metzendorf MI, Richter B. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. Cochrane Database Syst Rev 2021; 3: CD013498.
[http://dx.doi.org/10.1002/14651858.CD013498.pub2] [PMID: 33662147]
[http://dx.doi.org/10.1002/14651858.CD013498.pub2] [PMID: 33662147]
[31]
Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: Clinical and therapeutic implications. Lancet Diabetes Endocrinol 2019; 7(3): 221-30.
[http://dx.doi.org/10.1016/S2213-8587(18)30136-0] [PMID: 30115599]
[http://dx.doi.org/10.1016/S2213-8587(18)30136-0] [PMID: 30115599]
[32]
Rodbard D. Continuous glucose monitoring: A review of successes, challenges, and opportunities. Diabetes Technol Ther 2016; 18(Suppl. 2): S3-S13.
[http://dx.doi.org/10.1089/dia.2015.0417] [PMID: 26784127]
[http://dx.doi.org/10.1089/dia.2015.0417] [PMID: 26784127]
[33]
Beck RW, Bergenstal RM, Laffel LM, Pickup JC. Advances in technology for management of type 1 diabetes. Lancet 2019; 394(10205): 1265-73.
[http://dx.doi.org/10.1016/S0140-6736(19)31142-0] [PMID: 31533908]
[http://dx.doi.org/10.1016/S0140-6736(19)31142-0] [PMID: 31533908]
[34]
Sharma AK, Taneja G, Kumar A, et al. Insulin analogs: Glimpse on contemporary facts and future prospective. Life Sci 2019; 219: 90-9.
[http://dx.doi.org/10.1016/j.lfs.2019.01.011] [PMID: 30639280]
[http://dx.doi.org/10.1016/j.lfs.2019.01.011] [PMID: 30639280]
[35]
Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): A prospective observational real- world cohort study. Diabetes Care 2020; 43(2): 389-97.
[http://dx.doi.org/10.2337/dc19-1610] [PMID: 31843948]
[http://dx.doi.org/10.2337/dc19-1610] [PMID: 31843948]
[36]
Nana M, Moore SL, Ang E, Lee ZX, Bondugulapati LNR. Flash glucose monitoring: Impact on markers of glycaemic control and patient-reported outcomes in individuals with type 1 diabetes mellitus in the real-world setting. Diabetes Res Clin Pract 2019; 157: 107893.
[http://dx.doi.org/10.1016/j.diabres.2019.107893] [PMID: 31669628]
[http://dx.doi.org/10.1016/j.diabres.2019.107893] [PMID: 31669628]
[37]
Pintus D, Ng SM. Freestyle libre flash glucose monitoring improves patient quality of life measures in children with Type 1 Diabetes Mellitus (T1DM) with appropriate provision of education and support by healthcare professionals. Diabetes Metab Syndr 2019; 13(5): 2923-6.
[http://dx.doi.org/10.1016/j.dsx.2019.07.054] [PMID: 31425957]
[http://dx.doi.org/10.1016/j.dsx.2019.07.054] [PMID: 31425957]
[38]
Polonsky WH, Hessler D, Ruedy KJ, Beck RW. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: Further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40(6): 736-41.
[http://dx.doi.org/10.2337/dc17-0133] [PMID: 28389582]
[http://dx.doi.org/10.2337/dc17-0133] [PMID: 28389582]
[39]
Ólafsdóttir AF, Polonsky W, Bolinder J, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther 2018; 20(4): 274-84.
[http://dx.doi.org/10.1089/dia.2017.0363] [PMID: 29608107]
[http://dx.doi.org/10.1089/dia.2017.0363] [PMID: 29608107]
[40]
Hoeks LB, Greven WL, de Valk HW. Real-time continuous glucose monitoring system for treatment of diabetes: A systematic review. Diabet Med 2011; 28(4): 386-94.
[http://dx.doi.org/10.1111/j.1464-5491.2010.03177.x] [PMID: 21392060]
[http://dx.doi.org/10.1111/j.1464-5491.2010.03177.x] [PMID: 21392060]
[41]
Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012; 1: CD008101.
[http://dx.doi.org/10.1002/14651858.CD008101.pub2] [PMID: 22258980]
[http://dx.doi.org/10.1002/14651858.CD008101.pub2] [PMID: 22258980]
[42]
Zhou Y, Deng H, Liu H, et al. Effects of novel flash glucose monitoring system on glycaemic control in adult patients with type 1 diabetes mellitus: Protocol of a multicentre randomised controlled trial. BMJ Open 2020; 10(12): e039400.
[http://dx.doi.org/10.1136/bmjopen-2020-039400] [PMID: 33277281]
[http://dx.doi.org/10.1136/bmjopen-2020-039400] [PMID: 33277281]
[43]
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805.
[http://dx.doi.org/10.1136/bmj.d3805] [PMID: 21737469]
[http://dx.doi.org/10.1136/bmj.d3805] [PMID: 21737469]
[44]
Galindo RJ, Aleppo G. Continuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology. Diabetes Res Clin Pract 2020; 170: 108502.
[http://dx.doi.org/10.1016/j.diabres.2020.108502] [PMID: 33065179]
[http://dx.doi.org/10.1016/j.diabres.2020.108502] [PMID: 33065179]
[45]
Edelman SV, Cavaiola TS, Boeder S, Pettus J. Utilizing continuous glucose monitoring in primary care practice: What the numbers mean. Prim Care Diabetes 2021; 15(2): 199-207.
[http://dx.doi.org/10.1016/j.pcd.2020.10.013] [PMID: 33257275]
[http://dx.doi.org/10.1016/j.pcd.2020.10.013] [PMID: 33257275]
[46]
Ghazanfar H, Rizvi SW, Khurram A, Orooj F, Qaiser I. Impact of insulin pump on quality of life of diabetic patients. Indian J Endocrinol Metab 2016; 20(4): 506-11.
[http://dx.doi.org/10.4103/2230-8210.183472] [PMID: 27366717]
[http://dx.doi.org/10.4103/2230-8210.183472] [PMID: 27366717]
[47]
Nimri R, Nir J, Phillip M. Insulin pump therapy. Am J Ther 2020; 27(1): e30-41.
[http://dx.doi.org/10.1097/MJT.0000000000001097] [PMID: 31833871]
[http://dx.doi.org/10.1097/MJT.0000000000001097] [PMID: 31833871]
[48]
Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous Subcutaneous Insulin Infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; (1): CD005103.
[http://dx.doi.org/10.1002/14651858.CD005103.pub2] [PMID: 20091571]
[http://dx.doi.org/10.1002/14651858.CD005103.pub2] [PMID: 20091571]
[49]
Mesbah NI, Taha NA, Rahme ZN, Sukkar FF, Omar DM. Experiences of adults using continuous subcutaneous insulin infusion: A qualitative study. Med Princ Pract 2020; 29(3): 255-61.
[http://dx.doi.org/10.1159/000503705] [PMID: 31557759]
[http://dx.doi.org/10.1159/000503705] [PMID: 31557759]
[50]
Payk M, Robinson T, Davis D, Atchan M. An integrative review of the psychosocial facilitators and challenges of continuous subcutaneous insulin infusion therapy in type 1 diabetes. J Adv Nurs 2018; 74(3): 528-38.
[http://dx.doi.org/10.1111/jan.13463] [PMID: 28960449]
[http://dx.doi.org/10.1111/jan.13463] [PMID: 28960449]
[51]
Riveline JP, Franc S, Biedzinski M, et al. Sexual activity in diabetic patients treated by continuous subcutaneous insulin infusion therapy. Diabetes Metab 2010; 36(3): 229-33.
[http://dx.doi.org/10.1016/j.diabet.2010.01.004] [PMID: 20303814]
[http://dx.doi.org/10.1016/j.diabet.2010.01.004] [PMID: 20303814]
[52]
Wu YP, Graves MM, Roberts MC, Mitchell AC. Is insulin pump therapy better than injection for adolescents with diabetes? Diabetes Res Clin Pract 2010; 89(2): 121-5.
[http://dx.doi.org/10.1016/j.diabres.2010.04.010] [PMID: 20488572]
[http://dx.doi.org/10.1016/j.diabres.2010.04.010] [PMID: 20488572]
[53]
Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: A comparative overview and future horizons. Expert Opin Drug Deliv 2016; 13(3): 389-400.
[http://dx.doi.org/10.1517/17425247.2016.1115013] [PMID: 26618219]
[http://dx.doi.org/10.1517/17425247.2016.1115013] [PMID: 26618219]
[54]
Malik FS, Taplin CE. Insulin therapy in children and adolescents with type 1 diabetes. Paediatr Drugs 2014; 16(2): 141-50.
[http://dx.doi.org/10.1007/s40272-014-0064-6] [PMID: 24458650]
[http://dx.doi.org/10.1007/s40272-014-0064-6] [PMID: 24458650]
[55]
Lipman TH, Willi SM, Lai CW, Smith JA, Patil O, Hawkes CP. Insulin pump use in children with type 1 diabetes: Over a decade of disparities. J Pediatr Nurs 2020; 55: 110-5.
[http://dx.doi.org/10.1016/j.pedn.2020.08.007] [PMID: 32889433]
[http://dx.doi.org/10.1016/j.pedn.2020.08.007] [PMID: 32889433]
[56]
Blackman SM, Raghinaru D, Adi S, et al. Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes 2014; 15(8): 564-72.
[http://dx.doi.org/10.1111/pedi.12121] [PMID: 24494980]
[http://dx.doi.org/10.1111/pedi.12121] [PMID: 24494980]
[57]
Rubin RR, Peyrot M. Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabetes Technol Ther 2012; 14(2): 143-51.
[http://dx.doi.org/10.1089/dia.2011.0162] [PMID: 22133037]
[http://dx.doi.org/10.1089/dia.2011.0162] [PMID: 22133037]
[58]
Cherubini V, Gesuita R, Bonfanti R, et al. Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study. Acta Diabetol 2014; 51(1): 43-51.
[http://dx.doi.org/10.1007/s00592-013-0466-x] [PMID: 23508374]
[http://dx.doi.org/10.1007/s00592-013-0466-x] [PMID: 23508374]
[59]
Lukács A, Kiss-Tóth E, Varga B, Soós A, Takác P, Barkai L. Benefits of continuous subcutaneous insulin infusion on quality of life. Int J Technol Assess Health Care 2013; 29(1): 48-52.
[http://dx.doi.org/10.1017/S0266462312000797] [PMID: 23270655]
[http://dx.doi.org/10.1017/S0266462312000797] [PMID: 23270655]
[60]
Hussain T, Akle M, Nagelkerke N, Deeb A. Comparative study on treatment satisfaction and health perception in children and adolescents with type 1 diabetes mellitus on multiple daily injection of insulin, insulin pump and sensor-augmented pump therapy. SAGE Open Med 2017; 5: 2050312117694938.
[http://dx.doi.org/10.1177/2050312117694938] [PMID: 28321303]
[http://dx.doi.org/10.1177/2050312117694938] [PMID: 28321303]
[61]
Birkebaek NH, Kristensen LJ, Mose AH, Thastum M. Quality of life in Danish children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion or multiple daily injections. Diabetes Res Clin Pract 2014; 106(3): 474-80.
[http://dx.doi.org/10.1016/j.diabres.2014.09.028] [PMID: 25451903]
[http://dx.doi.org/10.1016/j.diabres.2014.09.028] [PMID: 25451903]
[62]
McAuley SA, de Bock MI, Sundararajan V, et al. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: A randomised controlled trial protocol. BMJ Open 2018; 8(6): e020274.
[http://dx.doi.org/10.1136/bmjopen-2017-020274] [PMID: 29886443]
[http://dx.doi.org/10.1136/bmjopen-2017-020274] [PMID: 29886443]
[63]
Boughton CK, Hovorka R. Is an artificial pancreas (closed-loop system) for type 1 diabetes effective? Diabet Med 2019; 36(3): 279-86.
[http://dx.doi.org/10.1111/dme.13816] [PMID: 30183096]
[http://dx.doi.org/10.1111/dme.13816] [PMID: 30183096]
[64]
Faulds ER, Zappe J, Dungan KM. Real-world implications of Hybrid Close Loop (HCL) insulin delivery system. Endocr Pract 2019; 25(5): 477-84.
[http://dx.doi.org/10.4158/EP-2018-0515] [PMID: 30865545]
[http://dx.doi.org/10.4158/EP-2018-0515] [PMID: 30865545]
[65]
Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. Lancet 2018; 392(10155): 1321-9.
[http://dx.doi.org/10.1016/S0140-6736(18)31947-0] [PMID: 30292578]
[http://dx.doi.org/10.1016/S0140-6736(18)31947-0] [PMID: 30292578]
[66]
Battelino T, Omladič JŠ, Phillip M. Closed loop insulin delivery in diabetes. Best Pract Res Clin Endocrinol Metab 2015; 29(3): 315-25.
[http://dx.doi.org/10.1016/j.beem.2015.03.001] [PMID: 26051293]
[http://dx.doi.org/10.1016/j.beem.2015.03.001] [PMID: 26051293]
[67]
Schierloh U, Wilinska ME, Pit-Ten Cate IM, Baumann P, Hovorka R, De Beaufort C. Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: Potential advantage? A randomized cross-over trial. PLoS One 2019; 14(3): e0212013.
[http://dx.doi.org/10.1371/journal.pone.0212013] [PMID: 30849076]
[http://dx.doi.org/10.1371/journal.pone.0212013] [PMID: 30849076]
[68]
Wu Z, Luo S, Zheng X, et al. Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes. Ther Adv Endocrinol Metab 2020; 11: 2042018820950146.
[http://dx.doi.org/10.1177/2042018820950146] [PMID: 32922721]
[http://dx.doi.org/10.1177/2042018820950146] [PMID: 32922721]
[69]
Marques RMB, Rodrigues MLM, Marini ACB, Santos CRDC, Schincaglia RM. Associated factors with the quality of life of adolescents with type 1 diabetes. Clin Nutr ESPEN 2021; 42: 387-92.
[http://dx.doi.org/10.1016/j.clnesp.2020.12.018] [PMID: 33745610]
[http://dx.doi.org/10.1016/j.clnesp.2020.12.018] [PMID: 33745610]
[70]
Rehni AK, Dave KR. Impact of hypoglycemia on brain metabolism during diabetes. Mol Neurobiol 2018; 55(12): 9075-88.
[http://dx.doi.org/10.1007/s12035-018-1044-6] [PMID: 29637442]
[http://dx.doi.org/10.1007/s12035-018-1044-6] [PMID: 29637442]
[71]
Fisher L, Tang T, Polonsky W. Assessing quality of life in diabetes: I. A practical guide to selecting the best instruments and using them wisely. Diabetes Res Clin Pract 2017; 126: 278-85.
[http://dx.doi.org/10.1016/j.diabres.2016.10.018] [PMID: 28153545]
[http://dx.doi.org/10.1016/j.diabres.2016.10.018] [PMID: 28153545]
[72]
Bally L, Thabit H, Kojzar H, et al. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: An open-label, randomised, crossover study. Lancet Diabetes Endocrinol 2017; 5(4): 261-70.
[http://dx.doi.org/10.1016/S2213-8587(17)30001-3] [PMID: 28094136]
[http://dx.doi.org/10.1016/S2213-8587(17)30001-3] [PMID: 28094136]
[73]
Stahl-Pehe A, Landwehr S, Lange KS, et al. Impact of quality of life (QoL) on glycemic control (HbA1c) among adolescents and emerging adults with long-duration type 1 diabetes: A prospective cohort-study. Pediatr Diabetes 2017; 18(8): 808-16.
[http://dx.doi.org/10.1111/pedi.12487] [PMID: 28133885]
[http://dx.doi.org/10.1111/pedi.12487] [PMID: 28133885]
[74]
Khemakhem R, Dridi Y, Hamza M, et al. Living with type 1 diabetes mellitus: How does the condition affect children’s and adolescents’ quality of life? Arch Pediatr 2020; 27(1): 24-8.
[http://dx.doi.org/10.1016/j.arcped.2019.11.002] [PMID: 31776074]
[http://dx.doi.org/10.1016/j.arcped.2019.11.002] [PMID: 31776074]
[75]
Ueno K, Chujo D, Takahashi N, Ohsugi M, Ueki K, Kajio H. Patient satisfaction and clinical efficacy of flash glucose monitoring in patients with type 1 diabetes: A prospective, single-center, single-arm study. Diabetes Ther 2020; 11(8): 1883-90.
[http://dx.doi.org/10.1007/s13300-020-00859-1] [PMID: 32578134]
[http://dx.doi.org/10.1007/s13300-020-00859-1] [PMID: 32578134]
Article Metrics
21
1